ALZ-NET International Case Study Series: Exploring Eligibility Episode 2
Activity Available: June 2024 – June 2026
Education Activity Title: Case Study Series: Exploring Eligibility Episode 2
Education Activity Description: This webinar series uses a case-study approach to explore issues surrounding the eligibility of patients being evaluated for treatment with novel FDA-approved Alzheimer’s therapies, and discusses appropriate treatment protocols.
Jointly provided by Postgraduate Institute for Medicine and Alzheimer’s Association
Estimated time to complete activity: Approximately 60 minutes per webinar (1.00 Credits)
Learning Objectives:
-
Discuss patient treatment eligibility criteria for novel FDA-approved Alzheimer’s therapies
-
Understand treatment considerations for novel FDA-approved Alzheimer’s therapies
-
Discuss clinical questions that may arise at treatment sites
Faculty Disclosure Information
For questions, contact the clinical education staff: clinicaledu@alz.org
Accreditation Information
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Target Audience: This activity is intended to meet the educational needs of primary care clinicians including internists, family physicians, radiologists, neurologists, nurse practitioners and pharmacist who are seeking additional education in the assessment, diagnosis, treatment and ongoing health care of patients with cognitive impairment and dementia.
Statement of Purpose: A practice gap is the difference between what healthcare professionals should or could be doing and what they are currently doing. Using current evidence-based practices to bridge the gap between patient care and care recommendation, ensuring healthcare professionals are not only aware of current practice but are utilizing them in patient care settings. This will be accomplished by increasing competence and knowledge on treatment protocols in the dementia disease space through a targeted case-based education method to educate the clinical field on how to incorporate new treatment options into their care management plans.
Joint Accreditation
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Alzheimer's Association. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designations:
Physician Continuing Medical Education; The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ per webinar. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education: The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 contact hours per webinar. This activity is being presented without bias and without commercial support.